三重激动剂 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-22. Anything still debated is marked as such rather than presented as settled.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
化学修饰延长了分子在体内的停留时间，使较低频次的给药安排成为可能。脂肪酸侧链通过与白蛋白结合延缓清除，非天然氨基酸则降低酶解速率。这些修饰同时改变分子的溶解性与稳定性，需要在制剂设计和储存条件中一并考虑。修饰引入的免疫原性风险也属于开发过程中需要评估的项目。
该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。
retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Identification and purity assessment typically rely on reversed-phase high-performance liquid chromatography, often paired with mass spectrometry. Mass measurement confirms the expected molecular mass and can reveal truncations or modifications. Peptide mapping and sequencing techniques provide sequence-level confirmation when needed. Because related peptide impurities can behave similarly in a single method, orthogonal techniques are usually combined. Reported purity values depend heavily on the method used and should be interpreted with that in mind.
Dissolution behavior depends on the amino acid sequence, the counterion content, and the buffer chosen. Many peptides disperse readily in water or mild aqueous buffers, while others require a small amount of organic co-solvent or a change in pH. Adsorption to plastic and glass surfaces can reduce the concentration of a solution over time, particularly at low concentrations. Filtration before analysis removes particulates, and aliquoting limits repeated freeze-thaw cycles that stress the material.
==== Mood and depression ==== Oxytocin produces antidepressant-like effects in animal models of depression, and a deficit of it may be involved in the pathophysiology of depression in humans. The antidepressant-like effects of oxytocin are not blocked by a selective antagonist of the oxytocin receptor, suggesting that these effects are not mediated by the oxytocin receptor. In accordance, unlike oxytocin, the selective non-peptide oxytocin receptor agonist WAY-267,464 does not produce antidepressant-like effects, at least in the tail suspension test. In contrast to WAY-267,464, carbetocin, a close analogue of oxytocin and peptide oxytocin receptor agonist, notably does produce antidepressant-like effects in animals. As such, the antidepressant-like effects of oxytocin may be mediated by modulation of a different target, perhaps the vasopressin V1A receptor where oxytocin is known to weakly bind as an agonist. Oxytocin mediates the antidepressant-like effects of sexual activity. A drug for sexual dysfunction, sildenafil enhances electrically evoked oxytocin release from the pituitary gland. In accordance, it may have promise as an antidepressant.
==== Psychiatric medications ==== Psychiatric medications include antipsychotics and antidepressants that have been shown to lengthen the QT interval and induce TdP, especially when given intravenously or in higher concentrations.
== References == Carpenter, Kenneth (1999). Eggs, Nests, and Baby Dinosaurs: A Look at Dinosaur Reproduction (Life of the Past), Indiana University Press; ISBN 0-253-33497-7. Deeming, D. C. and M. W. J. Ferguson (eds.) 1991. Egg incubation: its effect on embryonic development in birds and reptiles. Cambridge University Press, UK. 448pp. Glut, Donald F. (2003), "Appendix: Dinosaur Tracks and Eggs", Dinosaurs: The Encyclopedia. 3rd Supplement, Jefferson, North Carolina: McFarland & Company, Inc., pp. 613–652, ISBN 978-0-7864-1166-5 Horner, John R.; Weishampel, David B. (1996). "A comparative embryological study of two ornithischian dinosaurs - a correction". Nature. 383 (6595): 256–257. Bibcode:1996Natur.383..103H. doi:10.1038/383103b0. Mateus, I; Mateus, H; Antunes, MT; Mateus, O; Taquet, P; Ribeiro, V; Manuppella, G (1998). "Upper Jurassic theropod dinosaur embryos from Lourinhã (Portugal)". Memórias da Academia das Ciências de Lisboa. 37: 101–110. Moskvitch, Katia. "Eggs with the Oldest Known Embryos of a Dinosaur Found". BBC News. November 12, 2010. de Ricqlès, A.; Mateus, O.; Antunes, M. T.; Taquet, P. (2001). "Histomorphogenesis of embryos of Upper Jurassic theropods from Lourinhã (Portugal)". Comptes Rendus de l'Académie des Sciences, Série IIA. 332 (10): 647–656. Bibcode:2001CRASE.332..647D. doi:10.1016/s1251-8050(01)01580-4. Reisz, Robert R.; Scott, Diane; Sues, Hans-Dieter; Evans, David C.; Raath, Michael A. (2005). "Embryos of an Early Jurassic prosauropod dinosaur and their evolutionary significance" (PDF). Science. 309 (5735): 761–764.
Sources: en.wikipedia.org
=== Time and frequency === Government standard frequency and time signal services operate time radio stations which continuously broadcast extremely accurate time signals produced by atomic clocks, as a reference to synchronize other clocks. Examples are BPC, DCF77, JJY, MSF, RTZ, TDF, WWV, and YVTO. One use is in radio clocks and watches, which include an automated receiver that periodically (usually weekly) receives and decodes the time signal and resets the watch's internal quartz clock to the correct time, thus allowing a small watch or desk clock to have the same accuracy as an atomic clock. Government time stations are declining in number because GPS satellites and the Internet Network Time Protocol (NTP) provide equally accurate time standards.
proteoglycan Any heavily glycosylated protein, i.e. a core polypeptide with one or more covalently attached glycosaminoglycan chains. Proteoglycans are therefore considered a subclass of glycoproteins in which the carbohydrate units are long, linear polysaccharide polymers containing amino sugars and generally bearing a net negative charge under physiological conditions due to the presence of sulfates and uronic acid groups. They are a major component of the extracellular matrix between animal cells, where they form large hydrated complexes commonly employed in connective tissues such as cartilage.
=== Sensors === Magnetohydrodynamic sensors are used for precise measurements of angular velocity in inertial navigation systems such as those used in aerospace engineering. Accuracy improves with sensor size. The sensor is capable of operating in harsh environments.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
指同一个分子能激活 GIP、GLP-1 和胰高血糖素三类受体。它与只激活一到两种受体的同类分子在设计思路上有所区别。这种设计的目的在于覆盖更多代谢调节通路。